The General Hospital Corporation, operating as Massachusetts General Hospital (MGH), was awarded a $708,266 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant, titled "The Role of SALTE1 in Vascular Aging and Heart Failure with Preserved Ejection Fraction", will fund research to examine the causal role of the long non-coding RNA SALTE1 in regulating microvascular aging and its impact on heart failure with preserved ejection fraction (HFPEF). The three-year study, commencing on January 1, 2025, aims to shed new light on the pathophysiology of microvascular aging and HFPEF, and establish clinically relevant approaches targeting SALTE1 to combat HFPEF in aging individuals.
Generated 2/25/25, 1:42 AM